Krystal Biotech Statistics
Total Valuation
Krystal Biotech has a market cap or net worth of $8.02 billion. The enterprise value is $7.08 billion.
Important Dates
The next confirmed earnings date is Monday, May 4, 2026, before market open.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Krystal Biotech has 29.44 million shares outstanding. The number of shares has increased by 0.71% in one year.
| Current Share Class | 29.44M |
| Shares Outstanding | 29.44M |
| Shares Change (YoY) | +0.71% |
| Shares Change (QoQ) | +1.40% |
| Owned by Insiders (%) | 10.43% |
| Owned by Institutions (%) | 87.55% |
| Float | 23.33M |
Valuation Ratios
The trailing PE ratio is 39.84 and the forward PE ratio is 35.34. Krystal Biotech's PEG ratio is 0.64.
| PE Ratio | 39.84 |
| Forward PE | 35.34 |
| PS Ratio | 20.61 |
| Forward PS | 14.85 |
| PB Ratio | 6.52 |
| P/TBV Ratio | 6.58 |
| P/FCF Ratio | 42.46 |
| P/OCF Ratio | 39.94 |
| PEG Ratio | 0.64 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 43.43, with an EV/FCF ratio of 37.45.
| EV / Earnings | 34.54 |
| EV / Sales | 18.18 |
| EV / EBITDA | 43.43 |
| EV / EBIT | 43.87 |
| EV / FCF | 37.45 |
Financial Position
The company has a current ratio of 9.95, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.95 |
| Quick Ratio | 9.28 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | 0.05 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 18.91% and return on invested capital (ROIC) is 39.46%.
| Return on Equity (ROE) | 18.91% |
| Return on Assets (ROA) | 8.44% |
| Return on Invested Capital (ROIC) | 39.46% |
| Return on Capital Employed (ROCE) | 13.10% |
| Weighted Average Cost of Capital (WACC) | 7.20% |
| Revenue Per Employee | $1.32M |
| Profits Per Employee | $694,342 |
| Employee Count | 295 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 0.69 |
Taxes
| Income Tax | -15.36M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +64.37% in the last 52 weeks. The beta is 0.54, so Krystal Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +64.37% |
| 50-Day Moving Average | 262.83 |
| 200-Day Moving Average | 214.81 |
| Relative Strength Index (RSI) | 56.37 |
| Average Volume (20 Days) | 265,690 |
Short Selling Information
The latest short interest is 3.14 million, so 10.66% of the outstanding shares have been sold short.
| Short Interest | 3.14M |
| Short Previous Month | 2.89M |
| Short % of Shares Out | 10.66% |
| Short % of Float | 13.45% |
| Short Ratio (days to cover) | 11.08 |
Income Statement
In the last 12 months, Krystal Biotech had revenue of $389.13 million and earned $204.83 million in profits. Earnings per share was $6.84.
| Revenue | 389.13M |
| Gross Profit | 366.08M |
| Operating Income | 161.30M |
| Pretax Income | 189.47M |
| Net Income | 204.83M |
| EBITDA | 162.92M |
| EBIT | 161.30M |
| Earnings Per Share (EPS) | $6.84 |
Full Income StatementBalance Sheet
The company has $827.79 million in cash and $9.34 million in debt, with a net cash position of $946.52 million or $32.16 per share.
| Cash & Cash Equivalents | 827.79M |
| Total Debt | 9.34M |
| Net Cash | 946.52M |
| Net Cash Per Share | $32.16 |
| Equity (Book Value) | 1.22B |
| Book Value Per Share | 41.78 |
| Working Capital | 921.66M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $200.87 million and capital expenditures -$11.95 million, giving a free cash flow of $188.91 million.
| Operating Cash Flow | 200.87M |
| Capital Expenditures | -11.95M |
| Depreciation & Amortization | 1.62M |
| Net Borrowing | n/a |
| Free Cash Flow | 188.91M |
| FCF Per Share | $6.42 |
Full Cash Flow StatementMargins
Gross margin is 94.08%, with operating and profit margins of 41.45% and 52.64%.
| Gross Margin | 94.08% |
| Operating Margin | 41.45% |
| Pretax Margin | 48.69% |
| Profit Margin | 52.64% |
| EBITDA Margin | 41.87% |
| EBIT Margin | 41.45% |
| FCF Margin | 48.55% |
Dividends & Yields
Krystal Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.71% |
| Shareholder Yield | -0.71% |
| Earnings Yield | 2.55% |
| FCF Yield | 2.36% |
Analyst Forecast
The average price target for Krystal Biotech is $297.60, which is 9.20% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $297.60 |
| Price Target Difference | 9.20% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 21.35% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Krystal Biotech has an Altman Z-Score of 27.2 and a Piotroski F-Score of 6.
| Altman Z-Score | 27.2 |
| Piotroski F-Score | 6 |
